MyFinsight
Home
Blog
About
Net loss
attributable to common...
-$152,216K
(16.32%↑ Y/Y)
Net loss
attributable to redeemable...
-$3,675K
(-98.11%↓ Y/Y)
Net loss
-$155,891K
(15.17%↑ Y/Y)
Loss before income
taxes
-$155,891K
(14.18%↑ Y/Y)
Product
$222,440K
Royalty
$15,432K
License And Service
$5,804K
Loss from operations
-$107,079K
(20.26%↑ Y/Y)
Total other expense,
net
-$48,812K
(-3.02%↓ Y/Y)
Total revenues, net
$243,676K
(120.39%↑ Y/Y)
Interest income
$6,659K
(70.83%↑ Y/Y)
Other income, net
$5,587K
(-14.68%↓ Y/Y)
Total operating costs
and expenses
$350,755K
(43.26%↑ Y/Y)
Noncash interest
expense on deferred...
$41,345K
Interest expense
$13,278K
(-64.72%↓ Y/Y)
Net loss from equity
method investments
-$6,435K
(68.13%↑ Y/Y)
Selling, general and
administrative
$186,261K
(44.22%↑ Y/Y)
Research and development
$149,448K
(34.36%↑ Y/Y)
Total cost of revenues
$15,046K
(311.88%↑ Y/Y)
Product
$10,528K
License Services And
Royalty
$4,518K
Back
Back
Income Statement
BridgeBio Pharma, Inc. (BBIO)
BridgeBio Pharma, Inc. (BBIO)
source: myfinsight.com